Gerrit van Hall

Gerrit van Hall

Auto-generated profile, based on publicly available information

Gerrit van Hall

Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2000 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
ASAdam Steensberg
Adam Steensberg
GHGerrit van Hall
Gerrit van Hall
TOTakuya Osada
Takuya Osada
Massimo SacchettiMassimo Sacchetti
Massimo Sacchetti
BSBengt Saltin
Bengt Saltin
BPBente Klarlund Pedersen
Bente Klarlund Pedersen

1 July 2003 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
GHGerrit van Hall
Gerrit van Hall
ASAdam Steensberg
Adam Steensberg
Massimo SacchettiMassimo Sacchetti
Massimo Sacchetti
CFChristian Fischer
Christian Fischer
CKCharlotte Keller
Charlotte Keller
BPBente Klarlund Pedersen
Bente Klarlund Pedersen
Although IL-6 is a key modulator of immune function, it also plays a role in regulating substrate metabolism. To determine whether IL-6 affects lipid metabolism, 18 healthy men were infused for 3 h with saline (Con; n = 6) or a high dose (High-rhIL6; n = 6) or a low dose (Low-rhIL6; n = 6) of recombinant human IL-6 (rhIL-6). The IL-6 concentration during Con, Low-rhIL6, and High-rhIL6 was at a steady state after 30 min of infusion at approximately 4, 140, and 320 pg/ml, respectively. Either dose of rhIL-6 was associated with a similar increase in fatty acid (FA) concentration and endogenous FA rate of appearance (Ra) from 90 min after the start of the infusion. The FA concentration and FA Ra continued to increase until the cessation of rhIL-6 infusion, reaching levels approximately 50% greater than Con values. The elevated levels reached at the end of rhIL-6 infusion persisted at least 3 h postinfusion. Triacylglycerol concentrations were unchanged during rhIL-6 infusion, whereas whole body fat oxidation increased after the second hour of rhIL-6 infusion. Of note, during Low-rhIL6, the induced elevation in FA concentration and FA Ra occurred in the absence of any change in adrenaline, insulin, or glucagon, and no adverse side effects were observed. In conclusion, the data identify IL-6 as a potent modulator of fat metabolism in humans, increasing fat oxidation and FA reesterification without causing hypertriacylglyceridemia.

1 April 2009 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Closed access
GHGerrit van Hall
Gerrit van Hall
MSMorten Stømstad
Morten Stømstad
PRPeter Rasmussen
Peter Rasmussen
ØJØle Jans
Øle Jans
MZMorten Zaar
Morten Zaar
HNHenning B Nielsen
Henning B Nielsen
Lactate is a potential energy source for the brain. The aim of this study was to establish whether systemic lactate is a brain energy source. We measured in vivo cerebral lactate kinetics and oxidation rates in 6 healthy individuals at rest with and without 90 mins of intravenous lactate infusion (36 μmol per kg bw per min), and during 30mins of cycling exercise at 75% of maximal oxygen uptake while the lactate infusion continued to establish arterial lactate concentrations of 0.89 ± 0.08, 3.9 ± 0.3, and 6.9 ± 1.3 mmol/L, respectively. At rest, cerebral lactate utilization changed from a net lactate release of 0.06 ± 0.01 to an uptake of 0.16 ± 0.07 mmol/min during lactate infusion, with a concomitant decrease in the net glucose uptake. During exercise, the net cerebral lactate uptake was further increased to 0.28 ± 0.16 mmol/min. Most 13C-label from cerebral [1-13C]lactate uptake was released as 13CO2 with 100% ± 24%, 86% ± 15%, and 87% ± 30% at rest with and without lactate infusion and during exercise, respectively. The contribution of systemic lactate to cerebral energy expenditure was 8% ± 2%, 19% ± 4%, and 27% ± 4% for the respective conditions. In conclusion, systemic lactate is taken up and oxidized by the human brain and is an important substrate for the brain both under basal and hyperlactatemic conditions.

21 April 2009 in Circulation
Verified
Journal Article
Closed access
BDBrian G. Drew
Brian G. Drew
SDStephen J. Duffy
Stephen J. Duffy
MFMelissa F. Formosa
Melissa F. Formosa
ANAlaina K. Natoli
Alaina K. Natoli
DHDarren C. Henstridge
Darren C. Henstridge
BKBronwyn A. Kingwell
Bronwyn A. Kingwell
Background— Low plasma high-density lipoprotein (HDL) is associated with elevated cardiovascular risk and aspects of the metabolic syndrome. We hypothesized that HDL modulates glucose metabolism via elevation of plasma insulin and through activation of the key metabolic regulatory enzyme, AMP-activated protein kinase, in skeletal muscle. Methods and Results— Thirteen patients with type 2 diabetes mellitus received both intravenous reconstituted HDL (rHDL: 80 mg/kg over 4 hours) and placebo on separate days in a double-blind, placebo-controlled crossover study. A greater fall in plasma glucose from baseline occurred during rHDL than during placebo (at 4 hours rHDL=−2.6±0.4; placebo=−2.1±0.3mmol/L; P =0.018). rHDL increased plasma insulin (at 4 hours rHDL=3.4±10.0; placebo= −19.2±7.4 pmol/L; P =0.034) and also the homeostasis model assessment β-cell function index (at 4 hours rHDL=18.9±5.9; placebo=8.6±4.4%; P =0.025). Acetyl-CoA carboxylase β phosphorylation in skeletal muscle biopsies was increased by 1.7±0.3-fold after rHDL, indicating activation of the AMP-activated protein kinase pathway. Both HDL and apolipoprotein AI increased glucose uptake (by 177±12% and 144±18%, respectively; P <0.05 for both) in primary human skeletal muscle cell cultures established from patients with type 2 diabetes mellitus (n=5). The mechanism is demonstrated to include stimulation of the ATP-binding cassette transporter A1 with subsequent activation of the calcium/calmodulin-dependent protein kinase kinase and the AMP-activated protein kinase pathway. Conclusions— rHDL reduced plasma glucose in patients with type 2 diabetes mellitus by increasing plasma insulin and activating AMP-activated protein kinase in skeletal muscle. These findings suggest a role for HDL-raising therapies beyond atherosclerosis to address type 2 diabetes mellitus.

1 December 2001 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
ASAdam Steensberg
Adam Steensberg
MFMark A. Febbraio
Mark A. Febbraio
TOTakuya Osada
Takuya Osada
PSPeter Schjerling
Peter Schjerling
GHGerrit van Hall
Gerrit van Hall
BPBente Klarlund Pedersen
Bente Klarlund Pedersen

1 July 2010 in Acta Physiologica
Verified
Journal Article
Closed access
PDF file
GHGerrit van Hall
Gerrit van Hall